Article Details

Roche gets FDA priority review for Evrysdi to treat SMA in new-borns

Retrieved on: 2022-01-27 11:17:19

Tags for this article:

Click the tags to see associated articles and topics

Roche gets FDA priority review for Evrysdi to treat SMA in new-borns. View article details on hiswai:

Excerpt

Roche has received the US FDA priority review for its Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in new-borns.

Article found on: www.pharmaceutical-business-review.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up